Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

TalkTalk reportedly secures £100m lifeline from Ares

(Sharecast News) - TalkTalk has secured a £100m investment from Ares Management, it was reported on Friday, as part of a wider effort to ease financial pressures on the telecoms and broadband group According to Sky News, the funding, which would be provided in two tranches with an initial £60m expected shortly, formed part of a broader £200m package that also includes asset sales and deferred interest payments.

The agreement followed ongoing discussions with bondholders over the company's future structure, including a potential break-up involving the sale of its consumer business and PXC, its wholesale and network arm.

However, the disposals were not expected to take place in the near term.

In addition to the Ares funding, Sky said TalkTalk had already raised £50m through the sale of non-core customers to Utility Warehouse earlier this year.

The company had also reached an in-principle agreement to defer and capitalise cash interest payments worth around £60m.

TalkTalk, which has over three million broadband customers, had been struggling with a stretched balance sheet despite completing a £1.2bn refinancing in 2024.

It had appointed advisers from Alvarez & Marsal to strengthen its financial operations.

Bondholders had been pressing the company to secure additional funding amid growing operational challenges.

The company had also been involved in a dispute with BT Group's infrastructure division, Openreach, which the Financial Times reported last month could prevent TalkTalk from adding new customers due to outstanding payments.

Neither TalkTalk nor Ares had publicly commented on the reports by Friday lunchtime.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.